Healthcare
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolioWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. “We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and
About this update from Kala Bio, Inc.
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer. "We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape," said Ron Renaud, President and Chief Executive Officer of Kailera. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new options to people living with obesity." "Obesity is one of the most significant healthcare challenges facing society today, and continued innovation will be essential to meeting the needs of patients, providers, and healthcare systems," said Kathleen Tregoning, Chief Corporate Affairs Officer of Kailera. "Kailera is building a differentiated portfolio designed to expand treatment options in this dynamic field. I am excited to join the company at this important stage of growth and look forward to fostering engagement with stakeholders, supporting a policy environment that enables continued innovation, and helping build understanding of Kailera's vision, science, and progress among the communities we serve." Kathleen brings more than two decades of experience leading global corporate affairs organizations and guiding innovative biopharmaceutical companies through complex policy, regulatory, reputational, and stakeholder environments. Kathleen previously served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, where she helped lead the neuroscience company through a period of significant growth prior to its acquisition by AbbVie in 2024. Prior to joining Cerevel, she was Executive Vice President, External Affairs at Sanofi, where she led a global organization responsible for developing external engagement strategies, shaping healthcare policy, and advancing access to innovative therapies. She spent more than a decade at Biogen in positions of increasing responsibility, ultimately serving as Senior Vice President, Corporate Affairs, where she led communications, patient advocacy, public policy, and government affairs activities across the company's global business. Earlier in her career, she was a professional staff member in health policy for multiple committees of the United States Congress.